Cadrenal shares surge 10.95% premarket after announcing collaboration with Abbott for Tecarfarin's Phase 3 trial.

Cadrenal Therapeutics (NASDAQ:CVKD) surged 10.95% in premarket trading following the announcement of advancements in Tecarfarin development, including plans to initiate a Phase 3 trial for patients with End-Stage Kidney Disease transitioning to dialysis. The company also highlighted progress in manufacturing readiness and a collaboration with Abbott for a pivotal Phase 3 study in HeartMate 3™ LVAD patients, signaling strong clinical and strategic momentum. These developments, coupled with recent corporate updates on financial performance and trial preparations, underscore investor confidence in the drug’s potential and the company’s execution capabilities.